Publications scientifiques
Armelle Tontsa Tsamo
Augustin Ephrem Nkengfack
Nicole Lange
Autres affiliations : University Medical Center Hamburg-Eppendorf
Claudia Wegscheid
Autres affiliations : University Medical Center Hamburg-Eppendorf
C Loscher
Autres affiliations : University Medical Center Hamburg-Eppendorf
Gabriele Sass
Autres affiliations : University Medical Center Hamburg-Eppendorf · California Institute for Medical Research
Gisa Tiegs* (Auteur correspondant)
Autres affiliations : University Medical Center Hamburg-Eppendorf
PLoS ONE
Hepatocellular carcinoma (HCC) is extremely resistant towards pharmacological therapy. To date, the multi-kinase inhibitor Sorafenib is the only available therapeutic agent with the potential to prolong patient survival. Using the human hepatoma cell lines HepG2 and Huh7, we analyzed anti-cancer activities of 6 purified havanensin type limonoids isolated from the traditional African medicinal plant Trichilia rubescens Oliv. Our results show that two of the compounds, TR4 (TS3) and TR9 (Rubescin E) reduced hepatoma cell viability, but not primary hepatocyte viability, at TC50s of 5 to 10 μM. These were significantly lower than the TC50s for Sorafenib, the histone deacetylase inhibitor SAHA or 5-Fluoruracil. In comparison, TR3 (Rubescin D), a limonoid isolated in parallel and structurally highly similar to TR4 and TR9, did not interfere with hepatoma cell viability. Both, TR4 and TR9, but not TR3, induced apoptosis in hepatoma cells and interfered with NF-κB activation. TR4 as well as TR9 significantly supported anti-cancer activities of Sorafenib. In summary, the limonoids TR4 and TR9 exhibit anti-cancer activities and support Sorafenib effects in vitro, having the potential to support future HCC therapy.
